AzTrials
AzTrials

Stellate Ganglion BlockNCT07722052

Assessment of Diaphragmatic Function After Stellate Ganglion Block

An observational study of Stellate Ganglion Block and Diaphragm Ultrasound, run by Jose Manuel López González at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of our study was to evaluate the incidence of hemidiaphragmatic paralysis after ultrasound-guided stellate ganglion block (US-SGB) by assessing diaphragmatic excursion and diaphragmatic thickening fraction using diaphragm ultrasound. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Ultrasound-guided stellate ganglion block
Type of treatment
Surgery or procedure
How many people
15 participants
Where
1 siteSpain
Study dates
1 Dec 2024to 1 Jun 2026
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: After approval of the study by the Principality of Asturias Drug Research Ethics Committee (CEImPA), Spain, and obtaining informed consent from the participants, all consecutive patients undergoing a first diagnostic US-SGB for sympathetic nervous system-mediated disorders were prospectively included.

Who may be able to join

  • patients over 18 years of age.
  • patients with sympathetic nervous system-mediated disorders.

Who cannot join

  • patients younger than 18 years of age.
  • patients with severe chronic obstructive pulmonary disease.
  • previous diaphragmatic paralysis or neuromuscular disease.
  • inability to undergo diaphragmatic ultrasound.
  • patients with neck anatomy considered unsuitable for the procedure (including previous neck surgery, burns, extensive scarring or large goiters resulting in distortion of normal cervical anatomy).
  • contraindications to the interventional technique (such as infection at the puncture site, or refusal to provide consent).

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • FINBA

    Oviedo, Principality of Asturias, 33001

Other trials in Spain

About this study

Official title: Diaphragmatic Ultrasound and Spirometry After Ultrasound-guided Stellate Ganglion Block: a Prospective Observational Study

The objective of our study was to evaluate the incidence of hemidiaphragmatic paralysis after ultrasound-guided stellate ganglion block (US-SGB) by assessing diaphragmatic excursion and diaphragmatic thickening fraction using diaphragm ultrasound.

Read the detailed description

A prospective, single-center observational study was designed with the aim of evaluating diaphragmatic excursion and diaphragmatic thickening fraction, measured by ultrasound before and 30 minutes after US-SGB performed with 10 mL of 0.25% levobupivacaíne.

Being tested
Ultrasound-guided stellate ganglion block
Keywords
stellate ganglion block, diaphragm ultrasound, hemidiaphragmatic paralysis, diaphragmatic excursion, diaphragmatic thickening fraction, spirometry

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound-guided stellate ganglion blockProcedure or surgery

    US-SGB was performed at the C7 level using 10 ml of 0.25% levobupivacaíne.

Study groups in NCT07722052
Study groupRoleWhat they receive
US-SGBPatients with sympathetic nervous system-mediated disorders of the upper limb undergoing a first diagnostic ultrasound-guided stellate ganglion block (US-SGB).
Receives: Procedure: Ultrasound-guided stellate ganglion block

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diaphragmatic excursion

    Excursion of the diaphragmatic dome was assessed by a pulmonologist experienced in diaphragm ultrasound assessment. Once the dome was identified, excursion was measured in M-mode as the distance, in centimeters, between the end-expiratory and end-inspiratory positions during a vital capacity manoeuvre.

    Measured: The diaphragmatic excursion, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.

  2. Diaphragmatic thickening fraction

    The diaphragmatic thickening fraction was assessed by a pulmonologist experienced in diaphragm ultrasound assessment. Diaphragm thickness was measured, in centimeters, at end-inspiration and end-expiration during a vital capacity manoeuvre. Thickening fraction was calculated using the following formula and expressed as a percentaje:

    Thickening fraction = [(thickness at end-inspiration - thickness at end-expiration) / thickness at end-expiration] x 100.

    Measured: The diaphragmatic thickening, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.

Secondary outcomes (4)
  1. Forced vital capacity (FVC)

    Measure of the maximum exhaled volume of air (in liters, L) after a deep breath, on spirometry performed using a pneumotachograph spirometer.

    Measured: Spirometric parameters measured at baseline and 1 hour after US-SGB.

  2. Forced expiratory volume in 1 second (FEV1)

    Measure of the exhaled air volume (in liters, L) in the first second of the spirometry, performed using a pneumotachograph spirometer

    Measured: Spirometric parameters measured at baseline and 1 hour after US-SGB.

  3. Tiffeneau index (FEV1/FVC ratio)

    Ratio between the aforementioned FEV1 and FVC expressed in percentage (%), derived from the parameters obtained on spirometry.

    Measured: Spirometric parameters measured at baseline and 1 hour after US-SGB.

  4. Peripheral oxygen saturation (SpO2)

    Peripheral blood oxygen saturation (SpO2) expressed in percentage (%), measured using a digital pulse oximeter.

    Measured: Measured at baseline and 1 hour after US-SGB.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2026
  2. Study start1 Dec 2024
  3. Primary completion10 Dec 2025
  4. Study completion1 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
15 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07722052
Sponsor's protocol ID
2024.442
Status last verified
Jul 2026
First submitted
15 Jul 2026
Last updated
23 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Rafla C, Zitek T, Shalaby M. A systematic review of the respiratory effects of ultrasound-guided phrenic nerve block. Anesth Pain Med (Seoul). 2025 Oct;20(4):371-383. doi: 10.17085/apm.25214. Epub 2025 Sep 26.

    PubMed 41035293
  • Santana PV, Cardenas LZ, Albuquerque ALP, Carvalho CRR, Caruso P. Diaphragmatic ultrasound: a review of its methodological aspects and clinical uses. J Bras Pneumol. 2020 Nov 20;46(6):e20200064. doi: 10.36416/1806-3756/e20200064. eCollection 2020.

    PubMed 33237154
  • Sferrazza Papa GF, Pellegrino GM, Di Marco F, Imeri G, Brochard L, Goligher E, Centanni S. A Review of the Ultrasound Assessment of Diaphragmatic Function in Clinical Practice. Respiration. 2016;91(5):403-11. doi: 10.1159/000446518. Epub 2016 May 25.

    PubMed 27216909
  • Tsai EH, Nunez-Rodriguez E, Cata JP. Stellate ganglion block in perioperative practice: a narrative review. Br J Anaesth. 2026 Jan;136(1):179-196. doi: 10.1016/j.bja.2025.07.095. Epub 2025 Sep 29.

    PubMed 41027820
  • Motazedian P, Quinn N, Wells GA, Beauregard N, Lam E, Mathieu ME, Knoll W, Prosperi-Porta G, Ly V, Parlow S, Di Santo P, Abdel-Razek O, Jung R, Simard T, Jentzer JC, Mathew R, Ramirez FD, Hibbert B. Efficacy of stellate ganglion block in treatment of electrical storm: a systematic review and meta-analysis. Sci Rep. 2024 Oct 21;14(1):24719. doi: 10.1038/s41598-024-76663-9.

    PubMed 39433834
  • Kirkpatrick K, Khan MH, Deng Y, Shah KB. A Review of Stellate Ganglion Block as an Adjunctive Treatment Modality. Cureus. 2023 Feb 19;15(2):e35174. doi: 10.7759/cureus.35174. eCollection 2023 Feb.

    PubMed 36949968

Questions about this trial

What is this clinical trial studying?

An observational study of Stellate Ganglion Block and Diaphragm Ultrasound, run by Jose Manuel López González at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diaphragmatic excursion (time frame: The diaphragmatic excursion, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07722052, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in